Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician.
Reads0
Chats0
TLDR
A review of the main existing models of doxorubicin-induced cardiomyopathy using small laboratory animals is presented in this article, where the authors discuss the most significant challenges to the development of new methods of prevention and treatment, as well as to the unambiguous choice of a specific treatment regimen using the existing pharmacological tools.Abstract:
Today the pharmacological possibilities of treating cancer are expanding and as a result, life expectancy is increasing against the background of chemotherapy and supportive treatment. In the conditions of successful antitumor treatment, complications associated with its toxic effect on healthy tissues and organs began to come to the fore. Anthracycline cardiomyopathy was the first serious cardiovascular complication to draw the attention of oncologists and cardiologists around the world. Anthracycline drugs such as doxorubicin, epirubicin, idarubicin are still widely used in oncological practice to treat a wide range of solid and hematological malignancies. Doxorubicin-induced cardiomyopathy is closely associated with an increase in oxidative stress, as evidenced by reactive oxygen species (ROS) nduced damage such as lipid peroxidation, and decreased levels of antioxidants. Myofibrillar destruction and dysregulation of intracellular calcium are also important mechanisms, usually associated with doxorubicin-induced cardiotoxicity. Despite the abundance of data on various mechanisms involved in the implementation of doxorubicin-induced cardiotoxicity, a final understanding of the mechanism of the development of doxorubicin cardiomyopathy has not yet been formed. It poses the most significant challenges to the development of new methods of prevention and treatment, as well as to the unambiguous choice of a specific treatment regimen using the existing pharmacological tools. In order to resolve these issues new models that could reflect the development of the chemotherapy drugs effects are needed. In this review we have summarized and analyzed information on the main existing models of doxorubicin cardiomyopathy using small laboratory animals. In addition, this paper discusses further areas of research devoted to the development and validation of new improved models of doxorubicin cardiomyopathy suitable both for studying the mechanisms of its implementation and for the preclinical drugs effectiveness assessment.read more
Citations
More filters
Journal ArticleDOI
Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats
Hayder M Al-Kuraishy,Hany Akeel Al-hussaniy,Ali I Al-Gareeb,Walaa A. Negm,Aya Hassan El-Kadem,Gaber El-Saber Batiha,Nermeen N. Welson,Gomaa Mostafa-Hedeab,Ahmed H. Qasem,Carlos Adam Conte-Junior +9 more
TL;DR: Treatment with the combination of febuxostat and P. ginseng before DOX led to a significant improvement in the biomarkers of acute DOX-induced cardiotoxicity, and the potential mechanism of this combination was mainly mediated by the anti-inflammatory and antioxidant effects of P. Ginseng and febUXostat.
Journal ArticleDOI
Evaluation of the effect of Shengxian Decoction on doxorubicin-induced chronic heart failure model rats and a multicomponent comparative pharmacokinetic study after oral administration in normal and model rats.
Cui-Yun Huang,Shi Qiu,Xiangcheng Fan,Guangyang Jiao,Xun Zhou,Mei Sun,Nan Weng,Shouhong Gao,Xia Tao,Feng Zhang,Wansheng Chen +10 more
TL;DR: Wang et al. as mentioned in this paper investigated the benefit of Shengxian Decotion (SXT) in doxorubicin (DOX)-induced CHF rats and established a UHPLC-MS/MS method to simultaneously determine 18 key compounds in a subsequent comparative pharmacokinetic study.
Journal ArticleDOI
Large and Small Animal Models of Heart Failure With Reduced Ejection Fraction
TL;DR: A review of animal models of heart failure with reduced ejection fraction can be found in this article , where the authors evaluate the strength and weakness of each animal model to allow better selection of what animal models to use to address the scientific question proposed.
Journal ArticleDOI
Anticancer Drug-Induced Cardiotoxicity: Insights and Pharmacogenetics
Archana Adhikari,Syed Mohammed Basheeruddin Asdaq,Maitham A. Al Hawaj,Manodeep Chakraborty,Gayatri Thapa,Nihar Ranjan Bhuyan,Mohd. Imran,Mohammed Kanan Alshammari,Mohammed M. Alshehri,Aishah Ali Harshan,Abeer Alanazi,Bushra Dhuhayyan Alhazmi,Nagaraja Sreeharsha +12 more
TL;DR: The role of susceptible genes and radiation therapy in the occurrence of cardiotoxicity is also reviewed in this article, which emphasizes the protective role of antioxidants and future perspectives in anticancer drug-induced cardiotoxicities.
Journal ArticleDOI
Palmatine attenuates the doxorubicin-induced inflammatory response, oxidative damage and cardiomyocyte apoptosis.
TL;DR: In this article , a single intraperitoneal injection of DOX (15 mg/kg) in mice was used to establish an acute cardiotoxicity model, and the authors showed that PLT administration could reduce myocardial injury and improve cardiac dysfunction in DOX-treated mice.
References
More filters
Journal ArticleDOI
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
TL;DR: An overview of issues confirms that anthracyclines remain “evergreen” drugs with broad clinical indications but have still an improvable therapeutic index.
Journal ArticleDOI
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter +15 more
TL;DR: This document describes the development and use of angiotensin-converting enzyme, a non-volatile substance that acts as a “spatially aggregating substance” to reduce the chances of heart attack in women.
Journal ArticleDOI
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Sui Zhang,Xiaobing Liu,Xiaobing Liu,Tasneem Bawa-Khalfe,Long Sheng Lu,Yi Lisa Lyu,Leroy-Fong Liu,Edward T.H. Yeh,Edward T.H. Yeh +8 more
TL;DR: Cardiomyocyte-specific deletion of Top2b (encoding topoisomerase-IIβ) protects cardiomyocytes from doxorubicin-induced DNA double-strand breaks and transcriptome changes that are responsible for defective mitochondrial biogenesis and ROS formation.
Journal ArticleDOI
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
José Luis Zamorano,Patrizio Lancellotti,Daniel Rodriguez Muñoz,Victor Aboyans,Riccardo Asteggiano,Maurizio Galderisi,Gilbert Habib,Daniel J. Lenihan,Gregory Y.H. Lip,Alexander R. Lyon,Teresa López Fernández,Dania Mohty,Massimo F. Piepoli,Juan Tamargo,Adam Torbicki,Thomas M. Suter,Stephan Achenbach,Stefan Agewall,Lina Badimon,Gonzalo Barón-Esquivias,Helmut Baumgartner,Jeroen J. Bax,Héctor Bueno,Scipione Carerj,Veronica Dean,Çetin Erol,Donna Fitzsimons,Oliver Gaemperli,Paulus Kirchhof,Philippe Kolh,Petros Nihoyannopoulos,Piotr Ponikowski,Marco Roffi,Antonio Vaz Carneiro,Stephan Windecker +34 more
TL;DR: No abstract available Keywords: European Society of Cardiology; arrhythmias; cancer therapy; cardio-oncology; cardiotoxicity; chemotherapy; early detection; ischaemia; myocardial dysfunction; surveillance.
Journal ArticleDOI
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Yanti Octavia,Carlo G. Tocchetti,Kathleen L. Gabrielson,Stefan Janssens,Harry J.G.M. Crijns,An L. Moens +5 more
TL;DR: The authors have reviewed the molecular mechanisms of the pathogenesis of acute and chronic doxorubicin-induced cardiotoxicity and propose potential pharmacological interventions and treatment options to prevent or reverse this specific type of heart failure.